In Patient 1’s colorectal cancer, we detected a stop codon in APC, a well-documented cancer driver mutation in an essential tumor suppressor gene involved in colorectal cancer oncogenesis.23 We also identified mutations in ERBB2 (i.e. HER2), which have recently been found to be mutated in CRC and may represent a gene for targeted therapy in this cancer.24 Finally, we found mutations in NF1, also reported mutated previously in CRC.25 This evidence concerns the gene ERBB2 and neoplasm.